FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120490293> ?p ?o ?g. }

• W2120490293 endingPage "1197" @default.
• W2120490293 startingPage "1191" @default.
• W2120490293 abstract "Objectives: Human γδ T lymphocytes can recognise and kill non-small-cell lung cancer cells by Vγ9Vδ2 T-cell receptor and/or NKG2D. We have established large-scale ex vivo expansion of γδ T cells by zoledronate and interleukin-2. This pilot feasibility study evaluates the safety and potential anti-tumour effects of activated autologous γδ T cells administered intravenously to patients. Methods: Patients who had measurable foci of recurrent non-small-cell lung cancer were registered to undergo γδ T-cell immunotherapy, designed as a one-way, open, clinical research, after their informed consent. Mononuclear cells collected from peripheral blood of the patient were cultured with zoledronic acid and interleukin-2. After 2-week incubation, the γδ T-cell fraction was proliferated and it was intravenously reinfused to the patient. Results: Ten patients had undergone the γδ T-cell immunotherapy. They were administered autologous γδ T cells 3–12 times (mean = 6) every 2 weeks. No patient died during the study period. Adverse events, not directly related to the immunotherapy, were observed five times in four patients (grade 3 pneumonia in two and grade 1 coldness in three). According to the Response Evaluation Criteria in Solid Tumours, neither complete nor partial response was achieved in any patient; stable disease was observed in three; and progressive disease in five at 4 weeks after six consecutive injections of during immunotherapy. The Functional Assessment of Cancer Therapy-Biologic Response Modifier scores of the patients during immunotherapy were stable or improved, except for one patient who had suffered from pneumonia. The patients were followed up after immunotherapy for 240–850 days (median = 401 days). At the end of the observation, six patients were alive. Conclusions: We suggest that γδ T-cell immunotherapy might be safe and feasible for patients with recurrent non-small-cell lung cancer." @default.
• W2120490293 created "2016-06-24" @default.
• W2120490293 creator A5002395787 @default.
• W2120490293 creator A5003582794 @default.
• W2120490293 creator A5006420235 @default.
• W2120490293 creator A5013524621 @default.
• W2120490293 creator A5030744700 @default.
• W2120490293 creator A5070010133 @default.
• W2120490293 creator A5086766263 @default.
• W2120490293 creator A5091495712 @default.
• W2120490293 date "2010-05-01" @default.
• W2120490293 modified "2023-10-16" @default.
• W2120490293 title "A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆" @default.
• W2120490293 cites W1572267688 @default.
• W2120490293 cites W1966015047 @default.
• W2120490293 cites W1968697332 @default.
• W2120490293 cites W1978029914 @default.
• W2120490293 cites W1988862024 @default.
• W2120490293 cites W1999341606 @default.
• W2120490293 cites W2038032899 @default.
• W2120490293 cites W2043545955 @default.
• W2120490293 cites W2103436098 @default.
• W2120490293 cites W2104616589 @default.
• W2120490293 cites W2114951959 @default.
• W2120490293 cites W2115393755 @default.
• W2120490293 cites W2139403967 @default.
• W2120490293 cites W2139558439 @default.
• W2120490293 cites W2140457510 @default.
• W2120490293 cites W2148523692 @default.
• W2120490293 doi "https://doi.org/10.1016/j.ejcts.2009.11.051" @default.
• W2120490293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20137969" @default.
• W2120490293 hasPublicationYear "2010" @default.
• W2120490293 type Work @default.
• W2120490293 sameAs 2120490293 @default.
• W2120490293 citedByCount "152" @default.
• W2120490293 countsByYear W21204902932012 @default.
• W2120490293 countsByYear W21204902932013 @default.
• W2120490293 countsByYear W21204902932014 @default.
• W2120490293 countsByYear W21204902932015 @default.
• W2120490293 countsByYear W21204902932016 @default.
• W2120490293 countsByYear W21204902932017 @default.
• W2120490293 countsByYear W21204902932018 @default.
• W2120490293 countsByYear W21204902932019 @default.
• W2120490293 countsByYear W21204902932020 @default.
• W2120490293 countsByYear W21204902932021 @default.
• W2120490293 countsByYear W21204902932022 @default.
• W2120490293 countsByYear W21204902932023 @default.
• W2120490293 crossrefType "journal-article" @default.
• W2120490293 hasAuthorship W2120490293A5002395787 @default.
• W2120490293 hasAuthorship W2120490293A5003582794 @default.
• W2120490293 hasAuthorship W2120490293A5006420235 @default.
• W2120490293 hasAuthorship W2120490293A5013524621 @default.
• W2120490293 hasAuthorship W2120490293A5030744700 @default.
• W2120490293 hasAuthorship W2120490293A5070010133 @default.
• W2120490293 hasAuthorship W2120490293A5086766263 @default.
• W2120490293 hasAuthorship W2120490293A5091495712 @default.
• W2120490293 hasBestOaLocation W21204902931 @default.
• W2120490293 hasConcept C10882517 @default.
• W2120490293 hasConcept C121608353 @default.
• W2120490293 hasConcept C126322002 @default.
• W2120490293 hasConcept C137061746 @default.
• W2120490293 hasConcept C143998085 @default.
• W2120490293 hasConcept C1491633281 @default.
• W2120490293 hasConcept C154317977 @default.
• W2120490293 hasConcept C202751555 @default.
• W2120490293 hasConcept C203014093 @default.
• W2120490293 hasConcept C2776090121 @default.
• W2120490293 hasConcept C2776256026 @default.
• W2120490293 hasConcept C2777371288 @default.
• W2120490293 hasConcept C2777701055 @default.
• W2120490293 hasConcept C2778690821 @default.
• W2120490293 hasConcept C2778822529 @default.
• W2120490293 hasConcept C2778867473 @default.
• W2120490293 hasConcept C2779134260 @default.
• W2120490293 hasConcept C54355233 @default.
• W2120490293 hasConcept C55493867 @default.
• W2120490293 hasConcept C71924100 @default.
• W2120490293 hasConcept C86803240 @default.
• W2120490293 hasConcept C8891405 @default.
• W2120490293 hasConcept C90924648 @default.
• W2120490293 hasConceptScore W2120490293C10882517 @default.
• W2120490293 hasConceptScore W2120490293C121608353 @default.
• W2120490293 hasConceptScore W2120490293C126322002 @default.
• W2120490293 hasConceptScore W2120490293C137061746 @default.
• W2120490293 hasConceptScore W2120490293C143998085 @default.
• W2120490293 hasConceptScore W2120490293C1491633281 @default.
• W2120490293 hasConceptScore W2120490293C154317977 @default.
• W2120490293 hasConceptScore W2120490293C202751555 @default.
• W2120490293 hasConceptScore W2120490293C203014093 @default.
• W2120490293 hasConceptScore W2120490293C2776090121 @default.
• W2120490293 hasConceptScore W2120490293C2776256026 @default.
• W2120490293 hasConceptScore W2120490293C2777371288 @default.
• W2120490293 hasConceptScore W2120490293C2777701055 @default.
• W2120490293 hasConceptScore W2120490293C2778690821 @default.
• W2120490293 hasConceptScore W2120490293C2778822529 @default.
• W2120490293 hasConceptScore W2120490293C2778867473 @default.
• W2120490293 hasConceptScore W2120490293C2779134260 @default.
• W2120490293 hasConceptScore W2120490293C54355233 @default.

• next